Literature DB >> 11742493

High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR.

L Perey1, J Benhattar, R Peters, P Jaunin, S Leyvraz.   

Abstract

In small-cell lung carcinoma (SCLC) tumour cell contamination of leukaphereses is unknown. The present study was performed to define appropriate markers for reverse transcriptase polymerase chain reaction (RT-PCR), then to assess the contamination rate of leukaphereses and corresponding bone marrow samples. Immunocytochemistry (ICC) and RT-PCR methods were also compared. Among the 33 patients included, analyses were performed in 16 who had multiple leukaphereses and 17 who had only bone marrow. Leukapheresis products and bone marrow were analysed by ICC using several specific monoclonal antibodies against neural-cell adhesion molecule (N-CAM), epithelial glycoprotein (EGP-40) and cytokeratins (CK). Samples were also analyzed by RT-PCR for expression for N-CAM, synaptophysin, neuron-specific enolase, chromogranin, cytokeratin-18/-19, CEA, EGP-40, apomucin type 1 (MUC-1) and human endothelial cell-specific molecule (ESM-1). Using ICC staining, contaminating tumour cells were detected in 34% of leukaphereses (27% in patients with limited disease and 43% in those with extensive disease). N-CAM was the most reliable marker for detection of contamination. For RT-PCR, CK-19 and CEA were the only appropriate markers. Positive signal rate in leukaphereses increased to 78% (89% for patients with limited disease and 67% for extensive disease). In bone marrow, both techniques were in agreement whereas in leukaphereses, RT-PCR was better than ICC. A high rate of tumour cell contamination was demonstrated not only in bone marrow but also in leukaphereses from SCLC patients. The most appropriate technique was RT-PCR mainly in patients with limited disease. (c) 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742493      PMCID: PMC2363973          DOI: 10.1054/bjoc.2001.2177

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  K K Fields; G J Elfenbein; W L Trudeau; J B Perkins; W E Janssen; L C Moscinski
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

Authors:  W P Steward; J von Pawel; U Gatzemeier; P Woll; N Thatcher; G Koschel; L Clancy; J Verweij; R de Wit; W Pfeifer; J Fennelly; M von Eiff; J Frisch
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19.

Authors:  A Schoenfeld; K H Kruger; J Gomm; H D Sinnett; J C Gazet; N Sacks; H G Bender; Y Luqmani; R C Coombes
Journal:  Eur J Cancer       Date:  1997-05       Impact factor: 9.162

4.  Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene.

Authors:  M Luppi; M Morselli; E Bandieri; M Federico; R Marasca; P Barozzi; M G Ferrari; M Savarino; A Frassoldati; G Torelli
Journal:  Ann Oncol       Date:  1996-08       Impact factor: 32.976

5.  Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.

Authors:  A Zippelius; P Kufer; G Honold; M W Köllermann; R Oberneder; G Schlimok; G Riethmüller; K Pantel
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

6.  ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines.

Authors:  P Lassalle; S Molet; A Janin; J V Heyden; J Tavernier; W Fiers; R Devos; A B Tonnel
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

7.  Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor.

Authors:  J L Passos-Coelho; A A Ross; D J Kahn; T J Moss; J M Davis; A M Huelskamp; S J Noga; N E Davidson; M J Kennedy
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

8.  Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations.

Authors:  F Pasini; G Pelosi; R Mostacci; A Santo; A Masotti; P Spagnolli; E Recaldin; G L Cetto
Journal:  Ann Oncol       Date:  1995-01       Impact factor: 32.976

9.  Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.

Authors:  P J Woll; J Hodgetts; L Lomax; F Bildet; V Cour-Chabernaud; N Thatcher
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.

Authors:  W Helfrich; R ten Poele; G J Meersma; N H Mulder; E G de Vries; L de Leij; E F Smit
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  6 in total

1.  Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin.

Authors:  Sumei Zhang; Li Zuo; Shuyu Gui; Qing Zhou; Wei Wei; Yuan Wang
Journal:  Mol Biol Rep       Date:  2011-06-17       Impact factor: 2.316

2.  Correlation between expression and differentiation of endocan in colorectal cancer.

Authors:  Li Zuo; Su-Mei Zhang; Ruo-Lei Hu; Hua-Qing Zhu; Qing Zhou; Shu-Yu Gui; Qiang Wu; Yuan Wang
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

3.  Biological and clinical implications of endocan in gastric cancer.

Authors:  Wenyan Zhao; Ming Sun; Shuqiang Li; Yong Wang; Jingang Liu
Journal:  Tumour Biol       Date:  2014-07-11

4.  Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy.

Authors:  Kazuki Kano; Kentaro Sakamaki; Naohide Oue; Yayoi Kimura; Itaru Hashimoto; Kentaro Hara; Yukio Maezawa; Toru Aoyama; Hirohito Fujikawa; Yukihiko Hiroshima; Takanobu Yamada; Hiroshi Tamagawa; Naoto Yamamoto; Takashi Ogata; Haruhiko Cho; Hiroyuki Ito; Manabu Shiozawa; Norio Yukawa; Takaki Yoshikawa; Soichiro Morinaga; Yasushi Rino; Wataru Yasui; Munetaka Masuda; Yohei Miyagi; Takashi Oshima
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Endocan as a prognostic biomarker of triple-negative breast cancer.

Authors:  Atsunobu Sagara; Katsuhide Igarashi; Maky Otsuka; Akihiro Kodama; Mutsumi Yamashita; Rei Sugiura; Takeshi Karasawa; Kazuhiko Arakawa; Michiko Narita; Naoko Kuzumaki; Minoru Narita; Yoshinori Kato
Journal:  Breast Cancer Res Treat       Date:  2016-11-25       Impact factor: 4.872

6.  Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Liang-Yu Lin; Yi-Chen Yeh; Chia-Huei Chu; Justin G S Won; Yi-Ming Shyr; Yee Chao; Chung-Pin Li; Shin-E Wang; Ming-Huang Chen
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.